Skip to main content

Advertisement

SpringerLink
Log in

Common and rare carcinomas of the thymus

  • Review and Perspectives
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Thymic carcinoma encompasses a diverse group of rare tumors that occur almost exclusively in the prevascular (anterior) mediastinum. Thymic carcinomas have a worse outcome than thymomas with a median time to death of under 3 years. These tumors lack the typical lobulation of thymomas, exhibit commonly more cytologic atypia, are associated with a desmoplastic stromal reaction, and lack thymocytes, features that distinguish them from thymomas. The most common thymic carcinoma is squamous cell carcinoma; other subtypes include mucoepidermoid carcinoma, NUT carcinoma, and adenocarcinoma, among others. Largely due to multi-institutional and global efforts and meta-analysis of case reports and series, some of the thymic carcinoma subtypes have been studied in more detail and molecular studies have also been performed. Morphology and immunophenotype for the vast majority of thymic carcinoma subtypes are similar to their counterparts in other organs. Therefore, the distinction between thymic carcinoma and metastatic disease, which is relatively common in the prevascular mediastinum, can be challenging and in general requires clinical and radiologic correlation. Although surgical resection is the treatment of choice, only 46 to 68% of patients with thymic carcinoma can undergo resection as many other tumors present at high stage with infiltration into vital neighboring organs. These patients are usually treated with chemotherapy and/or radiation. The search for better biomarkers for prognosis and treatment of thymic carcinomas is important for improved management of these patients and possible targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Koizumi T, Otsuki K, Tanaka Y, Noguchi T, Fukushuima T, Kobayashi T, Ozawa T, Sekiguchi N, Hamanaka K (2020) National incidence and initial therapy for thymic carcinoma in Japan: based on analysis of hospital-based cancer registry data, 2009-2015. Jpn J Clin Oncol 50:434–439

    Article  PubMed  Google Scholar 

  2. Roden AC, Fang W, Shen Y, Carter BW, White DB, Jenkins SM, Spears GM, Molina JR, Klang E, Segni MD, Ackman JB, Sanchez EZ, Girard N, Shumeri E, Revel MP, Chassagnon G, Rubinowitz A, Dicks D, Detterbeck F, Ko JP, Falkson CB, Sigurdson S, Segreto S, del Vecchio S, Palmieri G, Ottaviano M, Marino M, Korst R, Marom EM (2020) Distribution of mediastinal lesions across multi-institutional, international, radiology databases. J Thorac Oncol 15:568–579

    Article  PubMed  Google Scholar 

  3. Roden AC, Yi ES, Cassivi SD, Jenkins SM, Yi G, Aubry MC (2013) Clinicopathological features of thymic carcinomas and the impact of histopathological agreement on prognostical studies. Eur J Cardiothorac Surg 43:1131–1139

    Article  PubMed  Google Scholar 

  4. Sakane T, Murase T, Okuda K, Saida K, Masaki A, Yamada T, Saito Y, Nakanishi R, Inagaki H (2019) A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology 75:755–766

    Article  PubMed  Google Scholar 

  5. Hishida T, Nomura S, Yano M, Asamura H, Yamashita M, Ohde Y, Kondo K, Date H, Okumura M, Nagai K (2016) Japanese Association for Research on the T: long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide database study. Eur J Cardiothorac Surg 49:835–841

    Article  PubMed  Google Scholar 

  6. Chalabreysse L, Etienne-Mastroianni B, Adeleine P, Cordier JF, Greenland T, Thivolet-Bejui F (2004) Thymic carcinoma: a clinicopathological and immunohistological study of 19 cases. Histopathology 44:367–374

    Article  CAS  PubMed  Google Scholar 

  7. Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS (2018) Paraneoplastic syndromes and thymic malignancies: an examination of the international thymic malignancy interest group retrospective database. J Thorac Oncol 13:436–446

    Article  PubMed  Google Scholar 

  8. Liu HC, Hsu WH, Chen YJ, Chan YJ, Wu YC, Huang BS, Huang MH (2002) Primary thymic carcinoma. Ann Thorac Surg 73:1076–1081

    Article  PubMed  Google Scholar 

  9. Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J (2010) Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg 89:912–917

    Article  PubMed  Google Scholar 

  10. Okereke IC, Kesler KA, Freeman RK, Rieger KM, Birdas TJ, Ascioti AJ, Badve S, Nelson RP, Loehrer PJ (2012) Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg 93:1668–1673

    Article  PubMed  Google Scholar 

  11. Bhora FY, Chen DJ, Detterbeck FC, Asamura H, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, van Schil P (2014) The ITMIG/IASLC thymic epithelial tumors staging project: a proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors. J Thorac Oncol 9:S88–S96

    Article  PubMed  Google Scholar 

  12. Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Hsieh MS, Chang YL, Chao YT, Chang CH, Chih-Hsin Yang J (2019) Clinical outcomes of up-front surgery versus surgery after induction chemotherapy for thymoma and thymic carcinoma: a retrospective study. Clin Lung Cancer 20:e609–e618

    Article  PubMed  Google Scholar 

  13. Shen X, Jin Y, Shen L, Sun Y, Chen H, Li Y (2018) Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. Diagn Pathol 13:41

    Article  PubMed  PubMed Central  Google Scholar 

  14. Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN (2018) Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 19:347–355

    Article  CAS  PubMed  Google Scholar 

  15. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ, Ally A, Appelbaum EL, Auman JT, Balasundaram M, Balu S, Behera M, Beroukhim R, Berrios M, Blandino G, Bodenheimer T, Bootwalla MS, Bowen J, Brooks D, Carcano FM, Carlsen R, Carvalho AL, Castro P, Chalabreysse L, Chin L, Cho J, Choe G, Chuah E, Chudamani S, Cibulskis C, Cope L, Cordes MG, Crain D, Curley E, Defreitas T, Demchok JA, Detterbeck F, Dhalla N, Dienemann H, Edenfield WJ, Facciolo F, Ferguson ML, Frazer S, Fronick CC, Fulton LA, Fulton RS, Gabriel SB, Gardner J, Gastier-Foster JM, Gehlenborg N, Gerken M, Getz G, Heiman DI, Hobensack S, Holbrook A, Holt RA, Hoyle AP, Hutter CM, Ittmann M, Jefferys SR, Jones CD, Jones SJM, Kasaian K, Kim J, Kimes PK, Lai PH, Laird PW, Lawrence MS, Lin P, Liu J, Lolla L, Lu Y, Ma Y, Maglinte DT, Mallery D, Mardis ER, Marra MA, Martin J, Mayo M, Meier S, Meister M, Meng S, Meyerson M, Mieczkowski PA, Miller CA, Mills GB, Moore RA, Morris S, Mose LE, Muley T, Mungall AJ, Mungall K, Naresh R, Newton Y, Noble MS, Owonikoko T, Parker JS, Paulaskis J, Penny R, Perou CM, Perrin C, Pihl T, Radenbaugh A, Ramalingam S, Ramirez N, Rieker R, Roach J, Sadeghi S, Saksena G, Schein JE, Schmidt HK, Schumacher SE, Shelton C, Shelton T, Shi Y, Shih J, Sica G, Silveira HCS, Simons JV, Sipahimalani P, Skelly T, Sofia HJ, Soloway MG, Stuart J, Sun Q, Tam A, Tan D, Tarnuzzer R, Thiessen N, van den Berg DJ, Vasef MA, Veluvolu U, Voet D, Walter V, Wan Y, Wang Z, Warth A, Weis CA, Weisenberger DJ, Wilkerson MD, Wise L, Wong T, Wu HT, Wu Y, Yang L, Zhang J, Zmuda E (2018) The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 33:244–258 e210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G (2014) A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 46:844–849

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Enkner F, Pichlhofer B, Zaharie AT, Krunic M, Holper TM, Janik S, Moser B, Schlangen K, Neudert B, Walter K et al (2017) Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res 23:551–564

    Article  CAS  PubMed  Google Scholar 

  18. Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, di Chiara F, Mengoli MC, Rossi G (2012) Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol 23:2409–2414

    Article  CAS  PubMed  Google Scholar 

  19. Feng Y, Lei Y, Wu X, Huang Y, Rao H, Zhang Y, Wang F (2017) GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer 110:48–52

    Article  PubMed  Google Scholar 

  20. Tiseo M, Damato A, Longo L, Barbieri F, Bertolini F, Stefani A, Migaldi M, Gnetti L, Camisa R, Bordi P, Buti S, Rossi G (2017) Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Lung Cancer 104:24–30

    Article  PubMed  Google Scholar 

  21. Roden AC, Erickson-Johnson MR, Yi ES, Garcia JJ (2013) Analysis of MAML2 rearrangement in mucoepidermoid carcinoma of the thymus. Hum Pathol 44:2799–2805

    Article  CAS  PubMed  Google Scholar 

  22. Porubsky S, Rudolph B, Ruckert JC, Kuffer S, Strobel P, Roden AC, Jain D, Tousseyn T, Van Veer H, Huang J et al (2019) EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus. Histopathology 75:431–436

    Article  PubMed  Google Scholar 

  23. Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM (2012) Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 36:1222–1227

    Article  PubMed  PubMed Central  Google Scholar 

  24. Aesif SW, Aubry MC, Yi ES, Kloft-Nelson SM, Jenkins SM, Spears GM, Greipp PT, Sukov WR, Roden AC (2017) Loss of p16INK4A expression and homozygous CDKN2A deletion are associated with worse outcome and younger age in thymic carcinomas. J Thorac Oncol 12:860–871

    Article  PubMed  Google Scholar 

  25. Roden AC, Yi ES, Jenkins SM, Donovan JL, Cassivi SD, Garces YI, Marks RS, Aubry MC (2015) Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas. Hum Pathol 46:17–25

    Article  PubMed  Google Scholar 

  26. Taniguchi Y, Ishida M, Saito T, Ryota H, Utsumi T, Maru N, Matsui H, Hino H, Tsuta K, Murakawa T (2020) Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma. Sci Rep 10:12286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, Murata Y, Nagai K, Ochiai A (2009) Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod Pathol 22:1341–1350

    Article  CAS  PubMed  Google Scholar 

  28. Hayashi A, Fumon T, Miki Y, Sato H, Yoshino T, Takahashi K (2013) The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma. J Clin Exp Hematopathol 53:9–19

    Article  Google Scholar 

  29. Kornstein MJ, Rosai J (1998) CD5 labeling of thymic carcinomas and other nonlymphoid neoplasms. Am J Clin Pathol 109:722–726

    Article  CAS  PubMed  Google Scholar 

  30. Yamada Y, Tomaru U, Ishizu A, Kiuchi T, Marukawa K, Matsuno Y, Kasahara M (2011) Expression of proteasome subunit beta5t in thymic epithelial tumors. Am J Surg Pathol 35:1296–1304

    Article  PubMed  Google Scholar 

  31. Jeong JH, Pyo JS, Kim NY, Kang DW (2020) Diagnostic roles of immunohistochemistry in thymic tumors: differentiation between Thymic carcinoma and thymoma. Diagnostics (Basel) 10

  32. Brown JG, Familiari U, Papotti M, Rosai J (2009) Thymic basaloid carcinoma: a clinicopathologic study of 12 cases, with a general discussion of basaloid carcinoma and its relationship with adenoid cystic carcinoma. Am J Surg Pathol 33:1113–1124

    Article  PubMed  Google Scholar 

  33. Posligua L, Ylagan L (2006) Fine-needle aspiration cytology of thymic basaloid carcinoma: case studies and review of the literature. Diagn Cytopathol 34:358–366

    Article  PubMed  Google Scholar 

  34. Hamza A, Younes AI, Kalhor N (2019) Thymic mucoepidermoid carcinoma: a systematic review and meta-analysis. Adv Anat Pathol 26:341–345

    Article  CAS  PubMed  Google Scholar 

  35. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart, 4th edn. International Agency for Research on Cancer, Lyon

    Google Scholar 

  36. Prieto-Granada CN, Inagaki H, Mueller J (2015) Thymic mucoepidermoid carcinoma: report of a case with CTRC1/3-MALM2 molecular studies. Int J Surg Pathol 23:277–283

    Article  PubMed  Google Scholar 

  37. Prieto-Granada CN, Stevens T (2018) Multilocular thymic cyst with mucinous differentiation: a mimicker of thymic mucoepidermoid carcinoma. Int J Surg Pathol 26:35–36

    Article  PubMed  Google Scholar 

  38. Kalhor N, Weissferdt A, Moran CA (2017) Primary salivary gland type tumors of the Thymus. Adv Anat Pathol 24:15–23

    Article  PubMed  Google Scholar 

  39. Zhang G, Yu Z, Shen G, Chai Y, Liang C (2019) Association between Epstein-Barr virus and thymic epithelial tumors: a systematic review. Infect Agent Cancer 14:32

    Article  PubMed  PubMed Central  Google Scholar 

  40. Sekihara K, Okuma Y, Kawamoto H, Hosomi Y (2014) Clinical outcome of thymic lymphoepithelioma-like carcinoma: case report of a 14-year-old male. Oncol Lett 8:2183–2186

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kawagishi S, Ose N, Minami M, Funaki S, Kanou T, Kimura K, Taniguchi S, Morii E, Shintani Y (2019) Total thymectomy for thymic lymphoepithelioma-like carcinoma-report of two cases. Surg Case Rep 5:158

    Article  PubMed  PubMed Central  Google Scholar 

  42. Iezzoni JC, Gaffey MJ, Weiss LM (1995) The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol 103:308–315

    Article  CAS  PubMed  Google Scholar 

  43. Dai X, Zhao L, Peng F (2018) Primary clear cell carcinoma of the thymus and literature comparison of features. Cancer Manag Res 10:513–518

    Article  PubMed  PubMed Central  Google Scholar 

  44. Kwon AY, Han J, Chu J, Choi YS, Jeong BH, Ahn MJ, Ahn YC (2017) Histologic characteristics of thymic adenocarcinomas: clinicopathologic study of a nine-case series and a review of the literature. Pathol Res Pract 213:106–112

    Article  PubMed  Google Scholar 

  45. Maghbool M, Ramzi M, Nagel I, Bejarano P, Siebert R, Saeedzadeh A, Daneshbod Y (2013) Primary adenocarcinoma of the thymus: an immunohistochemical and molecular study with review of the literature. BMC Clin Pathol 13:17

    Article  PubMed  PubMed Central  Google Scholar 

  46. Oka S, Inoue M, Honda Y, Chikaishi Y, Yoshida J, Yasuda D, Tanaka M (2019) Thymic papillary adenocarcinoma coexisting with type A thymoma: a case report. Int J Surg Case Rep 57:142–144

    Article  PubMed  PubMed Central  Google Scholar 

  47. Kalhor N, Moran CA (2018) Primary thymic adenocarcinomas: a clinicopathological and immunohistochemical study of 16 cases with emphasis on the morphological spectrum of differentiation. Hum Pathol 74:73–82

    Article  CAS  PubMed  Google Scholar 

  48. Kitamura M, Okada H, Miyahara S, Matsunaga A, Kadomatsu Y, Itagaki S, Kiriu T (2020) Case of primary thymic papillary adenocarcinoma associated with type AB thymoma and thymic cysts. Pathol Int 70:370–372

    Article  PubMed  Google Scholar 

  49. Matsuno Y, Morozumi N, Hirohashi S, Shimosato Y, Rosai J (1998) Papillary carcinoma of the thymus: report of four cases of a new microscopic type of thymic carcinoma. Am J Surg Pathol 22:873–880

    Article  CAS  PubMed  Google Scholar 

  50. Hosaka Y, Tsuchida M, Umezu H, Eimoto T, Hashimoto T, Shinohara H, Hayashi J (2010) Primary thymic adenocarcinoma coexisting with type AB thymoma: a rare case with long-term survival. Gen Thorac Cardiovasc Surg 58:488–491 discussion 491-482

    Article  PubMed  Google Scholar 

  51. Rampisela D, Zreik R, Donner LR (2015) Thymic tumor with adenoid cystic carcinoma-like features: a study of a clinically favorable case followed for 9 years. Int J Surg Pathol 23:557–560

    Article  CAS  PubMed  Google Scholar 

  52. Di Tommaso L, Kuhn E, Kurrer M, Zettl A, Marx A, Muller-Hermelink HK, Roncalli M, Rosai J (2007) Thymic tumor with adenoid cystic carcinomalike features: a clinicopathologic study of 4 cases. Am J Surg Pathol 31:1161–1167

    Article  PubMed  Google Scholar 

  53. Yang MQ, Bai LL, Wang Z, Huang WJ, Jiang GY, Xu HT (2020) Primary thymic carcinoma with adenoid cystic carcinoma-like features: a case report and literature review. Medicine (Baltimore) 99:e21531

    Article  Google Scholar 

  54. Moser B, Schiefer AI, Janik S, Marx A, Prosch H, Pohl W, Neudert B, Scharrer A, Klepetko W, Mullauer L (2015) Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma. Am J Surg Pathol 39:541–548

    Article  PubMed  Google Scholar 

  55. Tamai M, Ishida M, Ebisu Y, Okamoto H, Miyasaka C, Ohe C, Uemura Y, Saito T, Murakawa T, Tsuta K (2018) Thymic enteric type adenocarcinoma: a case report with cytological features. Diagn Cytopathol 46:92–97

    Article  PubMed  Google Scholar 

  56. Sakanoue I, Hamakawa H, Fujimoto D, Imai Y, Minami K, Tomii K, Takahashi Y (2017) KRAS mutation-positive mucinous adenocarcinoma originating in the thymus. J Thorac Dis 9:E694–E697

    Article  PubMed  PubMed Central  Google Scholar 

  57. French CA (2018) NUT carcinoma: clinicopathologic features, pathogenesis, and treatment. Pathol Int 68:583–595

    Article  CAS  PubMed  Google Scholar 

  58. Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C (2018) Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol 36:3007–3014

    Article  CAS  PubMed  Google Scholar 

  59. Chau NG, Ma C, Danga K, Al-Sayegh H, Nardi V, Barrette R, Lathan CS, DuBois SG, Haddad RI, Shapiro GI et al (2020) An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 4:pkz094

    Article  PubMed  Google Scholar 

  60. Kalhor N, Moran CA (2019) Thymic epithelial neoplasms with rhabdomyomatous component: a clinicopathological and immunohistochemical study of 7 cases. Hum Pathol 83:100–105

    Article  PubMed  Google Scholar 

  61. Karino F, Yokose T, Matsukuma S, Miyagi Y, Murakami S, Ito H, Nakayama H, Yamada K (2016) Clonality analysis performed using human androgen receptor assay in a rare case of undifferentiated thymic carcinoma coexisting with type AB thymoma. Pathol Int 66:398–403

    Article  PubMed  Google Scholar 

  62. Thomas de Montpréville V, Ghigna MR, Lacroix L, Besse B, Broet P, Dartevelle P, Fadel E, Dorfmuller P (2013) Thymic carcinomas: clinicopathologic study of 37 cases from a single institution. Virchows Arch 462:307–313

    Article  PubMed  Google Scholar 

  63. Ishibashi H, Akamatsu H, Kojima K, Usui H, Akashi T, Sunamori M (2007) Good syndrome with thymic adenosquamous carcinoma--report of a case. Ann Thorac Cardiovasc Surg 13:50–52

    PubMed  Google Scholar 

  64. Tsuchida M, Umezu H, Hashimoto T, Shinohara H, Koike T, Hosaka Y, Eimoto T, Hayashi JI (2008) Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 62:321–325

    Article  PubMed  Google Scholar 

  65. Franke A, Strobel P, Fackeldey V, Schafer R, Goller T, Becker HP, Schoneich R, Muller-Hermelink HK, Marx A (2004) Hepatoid thymic carcinoma: report of a case. Am J Surg Pathol 28:250–256

    Article  CAS  PubMed  Google Scholar 

  66. Weissferdt A, Moran CA (2012) Micronodular thymic carcinoma with lymphoid hyperplasia: a clinicopathological and immunohistochemical study of five cases. Mod Pathol 25:993–999

    Article  PubMed  Google Scholar 

  67. Nonaka D, Rodriguez J, Rollo JL, Rosai J (2005) Undifferentiated large cell carcinoma of the thymus associated with Castleman disease-like reaction: a distinctive type of thymic neoplasm characterized by an indolent behavior. Am J Surg Pathol 29:490–495

    Article  PubMed  Google Scholar 

  68. Zhao Y, Gu H, Fan L, Han K, Yang J, Zhao H (2017) Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients. Eur J Cardiothorac Surg 52:33–38

    Article  PubMed  Google Scholar 

  69. NCCN: NCCN clinical practice guidelines in oncology (NCCN Guidelines ). Thymomas and Thymic Carcinomas.: NCCN.org; Version 1.2020

  70. Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N (2020) Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 21:843–850

    Article  CAS  PubMed  Google Scholar 

  71. Terra S, Mansfield AS, Vrana JA, Roden AC (2019) Heterogeneity of programmed death-ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences. Histopathology 74:364–367

    Article  PubMed  Google Scholar 

  72. Sakane T, Murase T, Okuda K, Takino H, Masaki A, Oda R, Watanabe T, Kawano O, Haneda H, Moriyama S, Saito Y, Yamada T, Nakanishi R, Inagaki H (2018) A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. Oncotarget 9:6993–7009

    Article  PubMed  PubMed Central  Google Scholar 

  73. Uchida N, Fujita K, Okamura M, Nakatani K, Mio T (2019) The clinical benefits of immune checkpoint inhibitor for thymic carcinomas approximately experience of single public hospital in Japan approximately. Respir Med Case Rep 26:39–41

    PubMed  Google Scholar 

  74. Okuma Y, Hosomi Y, Watanabe K, Yamada Y, Horio H, Maeda Y, Okamura T, Hishima T (2014) Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center. BMC Cancer 14:349

    Article  PubMed  PubMed Central  Google Scholar 

  75. Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, van Schil P (2014) The IASLC/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 9:S65–S72

    Article  PubMed  Google Scholar 

  76. Kondo K, Van Schil P, Detterbeck FC, Okumura M, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL et al (2014) The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 9:S81–S87

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine & Pathology, Mayo Clinic Rochester, Hilton 11, 200 First St SW, Rochester, MN, 55905, USA

    Anja C. Roden

  2. Department of Pathology, The National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

    Malgorzata Szolkowska

Authors
  1. Anja C. Roden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malgorzata Szolkowska
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors contributed to the design, writing, literature search, and editing of the manuscript.

Corresponding author

Correspondence to Anja C. Roden.

Ethics declarations

No research involving human participants and/or animals was performed.

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roden, A.C., Szolkowska, M. Common and rare carcinomas of the thymus. Virchows Arch 478, 111–128 (2021). https://doi.org/10.1007/s00428-020-03000-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-020-03000-6

Keywords

Search

Navigation